MedTrace Logo

Preclinical Imaging Biomarkers of Alzheimer's Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study

NCT05350514 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2023-11-30

No results posted yet for this study

Summary

The goal of the study is to characterize preclinical Alzheimer's Disease and related dementias (AD/ADRD) neuropathology in a selected group of young adults with youth-onset diabetes, and an age-similar group of young adults without diabetes.

Conditions

  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • Diabetes, Youth Onset

Interventions

DRUG

PI-2620 tracer

Following published manufacturer guidelines for Flutemetamol (VizamylTM), Flortaucipir (TauvidTM) and PI-2620 tracer administration162, all participants will be given a 370 MBq (10 mCi) single intravenous bolus (total volume 10mL) of the radiotracer, followed with an intravenous flush of 0.9% sodium chloride injection. Radiotracer administration and participant monitoring will be conducted by trained personnel from the CU-RIC.

Sponsors & Collaborators

  • American College of Radiology

    collaborator OTHER

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Allison Shapiro, PhD, MPH · University of Colorado, Denver

  • Christopher T Whitlow, MD, PhD · Wake Forest University Health Sciences

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-19
Primary Completion
2023-05-31
Completion
2023-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05350514 on ClinicalTrials.gov